세계의 반려동물용 암 치료제 시장 보고서(2025년)
Pet Cancer Therapeutics Global Market Report 2025
상품코드 : 1793385
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

반려동물용 암 치료제 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 10.6%를 나타내 6억 5,000만 달러로 성장할 전망입니다. 예측기간의 성장은 반려동물의 고령화, 암 치료의 진보, 수의종양학 서비스 증가, 반려동물 보험과 헬스케어 플랜, 반려동물 케어 서비스의 세계의 확대가 요인입니다. 예측기간의 주요 동향으로는 영양보조식품과 통합요법 증가, 표적진단검사의 이용가능성 증가, 수의사와 인간의 종양학의 제휴, 신규 화학요법제의 도입, 의식의 향상과 주인교육 등이 있습니다.

향후 5년간의 성장률 10.6%라고 하는 예측은 이 시장에 관한 전회의 예측으로부터 변경은 없습니다. 이 감소의 주요 원인은 미국과 다른 국가 간의 관세의 영향입니다. 국제적으로 조달되는 생물학적 제제 및 면역요법 입력에 대한 관세의 영향으로 반려동물의 첨단 종양학 치료에 대한 접근성과 가용성이 제한될 수 있습니다. 또한 상호 관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 늘어날 것으로 보입니다.

반려동물 헬스케어 지출 증가가 전망되기 때문에 반려동물용 암 치료제 시장의 확대가 전망됩니다. 반려동물의 건강 관리 지출에는 수의사 서비스, 투약 및 기타 건강 관리 관련 비용에 대한 자금이 포함됩니다. 반려동물의 건강에 투자하려고 하는 주인의 동향의 높아짐이, 반려동물 헬스케어에의 지출 증가에 반영되어, 반려동물용 암 치료제 수요 증가로 이어지고 있습니다. 예를 들어, 북미 반려동물 건강 보험 협회(NAPHIA)의 2023년 업계 현황 보고서에 따르면 2022년 말까지 미국 내 보험에 가입한 반려동물 수가 2021년 대비 22% 증가하여 480만 마리에 달한 것으로 나타났습니다. 이 반려동물 건강 관리 지출의 급증이 반려동물용 암 치료제 시장 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Pet cancer therapeutics involve the use of various treatments and medications to manage or cure cancer in pets. The choice of therapeutics depends on several factors such as the type and stage of cancer, as well as the pet's age and overall health.

The main types of pet cancer therapeutics are tailored to specific cancer types, including melanoma, mast cell cancer, lymphoma, and mammary and squamous cell cancer. Melanoma is a type of cancer that originates from pigment-producing cells called melanocytes. These therapeutics can be administered through various routes, including oral and injection methods, tailored for dogs, cats, and other animals. Different therapies employed in pet cancer treatment include chemotherapy, radiation therapy, immunotherapy, tomo therapy, and others. These therapies are utilized by veterinary hospitals, clinical pharmacies, retail pharmacies, online pharmacies, and other healthcare facilities focused on pet health.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a considerable impact on the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care products. Increased duties on imported veterinary medicines, diagnostic equipment, surgical tools, and pet care supplies have driven up operational costs for veterinary clinics, animal hospitals, and livestock health providers, forcing them to either raise service charges or absorb reduced profit margins. The livestock and agricultural industries are facing similar pressures, as tariffs on feed additives, vaccines, and breeding equipment push up production costs and complicate animal health management. Furthermore, retaliatory tariffs in major export markets have weakened demand for U.S.-manufactured veterinary products, adding to revenue challenges. To navigate these headwinds, the sector must now focus on local sourcing, preventive healthcare strategies, and digital veterinary solutions to control costs while continuing to deliver quality animal care.

The pet cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides pet cancer therapeutics market statistics, including pet cancer therapeutics industry global market size, regional shares, competitors with a pet cancer therapeutics market share, detailed pet cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pet cancer therapeutics industry. This pet cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pet cancer therapeutics market size has grown rapidly in recent years. It will grow from $0.39 billion in 2024 to $0.43 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to rise in pet ownership, advancements in veterinary medicine, increased awareness of pet health, humanization of pets, expansion of veterinary services.

The pet cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $0.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to growing aging pet population, advancements in cancer treatment, rising veterinary oncology services, pet insurance and healthcare plans, global expansion of pet care services. Major trends in the forecast period include rise in nutraceuticals and integrative therapies, increased availability of targeted diagnostic tests, collaboration between veterinary and human oncology, introduction of novel chemotherapeutic agents, growing awareness and pet owner education.

The forecast of 10.6% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff implications on biologics and immunotherapy inputs sourced internationally could limit accessibility and affordability of advanced pet oncology treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in pet healthcare expenditure is set to drive the expansion of the pet cancer therapeutics market. Pet healthcare expenditure encompasses the funds allocated for veterinary services, medications, and other healthcare-related costs for pets. The rising trend of pet owners' willingness to invest in their pets' well-being is reflected in the increased expenditure on pet healthcare, leading to a higher demand for pet cancer therapeutics. For example, the North American Pet Health Insurance Association's (NAPHIA) 2023 State of the Industry Report revealed a 22% increase in the total number of insured pets in the U.S. by the end of 2022, reaching 4.8 million, compared to 2021. This surge in pet healthcare expenditure is a driving force for the pet cancer therapeutics market.

The growth of the pet cancer therapeutics market is expected to be propelled by the increasing prevalence of pet cancer. Pet cancer involves abnormal and uncontrolled cell growth in domesticated animals, leading to tumor formation. The rising incidence of pet cancer is attributed to environmental toxins, pollutants, and genetic and lifestyle factors. Consequently, there is an escalating demand for advanced and effective cancer therapeutics for pets. According to the Veterinary Cancer Society's (VCS) 2022 predictions, approximately 1 in 4 dogs is diagnosed with cancer during their lifetime, with cancer being a primary cause of death among older pets. Additionally, the National Cancer Institute anticipates approximately 6 million new cancer cases in pets annually, with a projected increase in the coming years. The increasing prevalence of pet cancer is poised to drive the growth of the pet cancer therapeutics market.

Leading companies in the pet cancer therapeutics market are focusing on developing epigenetic technologies to enhance the efficacy of treatments and improve precision in targeting cancer cells, ultimately leading to better outcomes for pets diagnosed with cancer. Epigenetic technology involves techniques that modify gene expression without altering the underlying DNA sequence, thereby influencing cellular behavior and therapeutic results. For example, in April 2024, VolitionRx Limited, a US-based multinational epigenetics company, launched the Nu.Q Vet Cancer Test. This test operates on the Element i+ Analyzer and delivers rapid results-typically within approximately six minutes. It employs an enzyme-linked immunosorbent assay to detect circulating nucleosomes in the blood, which can serve as indicators of cancer presence.

Strategic partnerships are a significant approach adopted by major companies in the pet cancer therapeutics market to achieve superior disease control. This collaborative strategy involves leveraging each other's strengths and resources to attain mutual benefits and success. One such collaboration occurred in June 2022, when Germany-based pharmaceutical company Boehringer Ingelheim partnered with U.S.-based biopharmaceutical company CarthroniX. The collaboration focuses on identifying new small molecules to target cancers in dogs, potentially offering superior disease control. CarthroniX will supply the small molecules for evaluation by Boehringer Ingelheim, emphasizing their commitment to advancing oncology research in animal health and exploring new therapeutic options for the treatment of canine cancer.

In June 2024, Lantheus, a US-based company specializing in the development and commercialization of innovative imaging products and radiopharmaceuticals for diagnostic purposes in healthcare, acquired Life Molecular Imaging GmbH for an undisclosed sum. This acquisition is intended to enhance Lantheus's portfolio of diagnostic imaging solutions, expand its capabilities in molecular imaging, and strengthen its position within the healthcare market. Life Molecular Imaging GmbH, based in Germany, is dedicated to advancing imaging technologies, particularly in the realm of molecular imaging.

Major companies operating in the pet cancer therapeutics market include AB Science, Boehringer Ingelheim GmbH, Elanco Animal Health, ELIAS Animal Health, Zoetis Inc., Anivive Lifesciences Inc., QBiotics Group Ltd., Regeneus Ltd., VetDC Inc., PetCure Oncology at Veterinary Radiosurgery and Imaging Center, Torigen Pharmaceuticals Inc., virology and bacteriology, Nippon Zenyaku Kogyo Co. Ltd., Vivesto AB, Dechra Pharmaceuticals plc, Norbrook Laboratories Ltd., AdvaVet Inc., Oasmia Pharmaceuticals AB, Zenoaq Co. Ltd., Morphogenesis Inc., Sumitomo Pharma Animal Health Co., Vetivax, CarthroniX Inc.

North America was the largest region in the pet cancer therapeutics market in 2024. The regions covered in the pet cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pet cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pet cancer therapeutics market consists of revenues earned by entities by surgery and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pet Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pet cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pet cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pet cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Pet Cancer Therapeutics Market Characteristics

3. Pet Cancer Therapeutics Market Trends And Strategies

4. Pet Cancer Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pet Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

6. Pet Cancer Therapeutics Market Segmentation

7. Pet Cancer Therapeutics Market Regional And Country Analysis

8. Asia-Pacific Pet Cancer Therapeutics Market

9. China Pet Cancer Therapeutics Market

10. India Pet Cancer Therapeutics Market

11. Japan Pet Cancer Therapeutics Market

12. Australia Pet Cancer Therapeutics Market

13. Indonesia Pet Cancer Therapeutics Market

14. South Korea Pet Cancer Therapeutics Market

15. Western Europe Pet Cancer Therapeutics Market

16. UK Pet Cancer Therapeutics Market

17. Germany Pet Cancer Therapeutics Market

18. France Pet Cancer Therapeutics Market

19. Italy Pet Cancer Therapeutics Market

20. Spain Pet Cancer Therapeutics Market

21. Eastern Europe Pet Cancer Therapeutics Market

22. Russia Pet Cancer Therapeutics Market

23. North America Pet Cancer Therapeutics Market

24. USA Pet Cancer Therapeutics Market

25. Canada Pet Cancer Therapeutics Market

26. South America Pet Cancer Therapeutics Market

27. Brazil Pet Cancer Therapeutics Market

28. Middle East Pet Cancer Therapeutics Market

29. Africa Pet Cancer Therapeutics Market

30. Pet Cancer Therapeutics Market Competitive Landscape And Company Profiles

31. Pet Cancer Therapeutics Market Other Major And Innovative Companies

32. Global Pet Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pet Cancer Therapeutics Market

34. Recent Developments In The Pet Cancer Therapeutics Market

35. Pet Cancer Therapeutics Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기